Skip to main content
PolicySpeak
← All files
FAR

FARMAINDUSTRIA

Industry association · Spain · EU Transparency Register 025250318220-32

3
positions filed
in the 326 files tracked
3
legislative files
of 326 tracked
0
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

Who they are

Among the 1205 trade and business associations on this site, they rank #539 by legislative files engaged — a count of participation, not a measure of influence.

1.5
declared lobbying FTE
self-declared
€100K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2015
in the register since

Declares membership of

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).

Register category
Trade and business associations
Registered as
ASOCIACIÓN NACIONAL EMPRESARIAL DE LA INDUSTRIA FARMACÉUTICA (FARMAINDUSTRIA)
Head office
MADRID, Spain

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.

Track FARMAINDUSTRIA in PolicySpeak: request access →

Work at FARMAINDUSTRIA? so we know who speaks for it.

Follow the files FARMAINDUSTRIA engages with

One email on Tuesdays when a new position is filed on these 3 files, from FARMAINDUSTRIA or from anyone else on them. Only when there is something new.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Their record over time

FARMAINDUSTRIA filed 3 positions between 7 Mar 2025 and 13 Jul 2026, across 3 of the 326 legislative files tracked here.

2025 · 1 filed2026 · 2 filed

What they argued

Evaluation of the Public Procurement Directivesfiled 7 Mar 2025source

General public procurement legislation (Directive 2014/24/EU of the European Parliament and of the Council of 26 February 2014 on public procurement and repealing Directive 2004/18/EC (Directive 2014/24) has proven insufficient for hospital public procurement of medicinal products, in particular for the purchase of innovative medicinal products subject to exclusive industrial property rights.

Filed in Spanish · English published by the European Commission

Revision of EU rules on public procurementfiled 26 Jan 2026source

General public procurement legislation (Directive 2014/24/EU of the European Parliament and of the Council of 26 February 2014 on public procurement and repealing Directive 2004/18/EC (Directive 2014/24)) has proven insufficient for the hospital public purchase of medicinal products, in particular for the purchase of innovative medicinal products subject to exclusive industrial property rights.

Filed in Spanish · English published by the European Commission

European Biotech Actfiled 13 Jul 2026source

Farmaindustria appreciates the Regulation for its potential to strengthen the EU’s competitiveness, strategic autonomy and innovation capacity, although it could be more ambitious in the face of increasing global competition and investment pressure from other regions.

Filed in Spanish · English published by the European Commission

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Turns up on the same files

Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.

Showing 5 of 144.

Is this your organization?

Everything on this page comes from FARMAINDUSTRIA’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.